MYMD

NASDAQ

MyMD Pharmaceuticals Inc.

SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesIPO2014

News25/Ratings0

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.

Latest news

25 items

639dNEWS
TNF Pharmaceuticals Trades Under New Ticker "TNFA"
New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
639dPR
TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today
New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TNFA," effective before the market open today, July 24, 2024. The new trading symbol "TNFA" replaces the Company's previous trading symbol "MYMD" and coincides with the Company's previously announced corporat
641dNEWS
MyMD Pharmaceuticals Announces Corporate Rebranding To New Name TNF Pharmaceuticals, To Begin Under The New Trading Symbol "TNFA" Effective July 24, 2024
New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic systemCompany plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studiesTNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name "TNF Pharmaceuticals, Inc.," effective today. The Company's common stock,
641dPR
MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024 TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name "TNF Pharmaceuticals, Inc.," effective today. The Company's com
661dSEC
SEC Form DEF 14A filed by MyMD Pharmaceuticals Inc.
DEF 14A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
664dINSIDER
SEC Form 3 filed by new insider Friscia Stephen
3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
667dNEWS
Latest Key Hires & Board Changes In Cannabis Industry: Canopy Growth, Acreage And More
As Benzinga Cannabis Capital Conference returns to Chicago this Oct. 8-9 for its 19th edition, gathering top CEOs, investors and investors and leaders in the cannabis industry, let’s scroll through the latest leadership changes in the space. Get your tickets now before prices surge by following this link. Kicking off with Margaret Brodie, CEO of Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF), who has recently been nominated as an EY Entrepreneur Of The Year 2024 finalist in Pacific. The company shared the news in an X post earlier in June. Canadian cannabis giant Canopy Growth Corporation (TSX:WEED) (NASDAQ:CGC) recently appointed Ryan Keith, a senior commercial leader with over two d
668dSEC
MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
671dSEC
SEC Form S-3 filed by MyMD Pharmaceuticals Inc.
S-3 - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
672dSEC
Amendment: MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
8-K/A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
672dSEC
SEC Form PRE 14A filed by MyMD Pharmaceuticals Inc.
PRE 14A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
676dSEC
MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events
8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
676dNEWS
MyMD Pharmaceuticals Announces Dr. Mitchell Glass As President And CMO
676dPR
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm
689dNEWS
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Annexon (NASDAQ:ANNX) shares increased by 57.2% to $7.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $665.3 million. Fresh2 Group (NASDAQ:FRES) shares moved upwards by 36.08% to $0.48. The company's market cap stands at $11.8 million. SunLink Health Systems (AMEX:SSY) stock moved upwards by 32.45% to $0.8. The market value of their outstanding shares is at $5.6 million. Adlai Nortye (NASDAQ:ANL) stock moved upwards by 15.96% to $7.12. The market value of their outstanding shares is at $262.7 million. TRACON Pharma (NASDAQ:TCON) shares rose 15.74% to $1.47. The market value of their outstanding shares is at $3.9 million. Kindly MD (NASD
693dSEC
SEC Form D filed by MyMD Pharmaceuticals Inc.
D - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
693dSEC
SEC Form D filed by MyMD Pharmaceuticals Inc.
D - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
693dNEWS
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers MyMD Pharmaceuticals (NASDAQ:MYMD) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. Adaptimmune Therapeutics (NASDAQ:ADAP) stock moved upwards by 31.68% to $1.33. The market value of their outstanding shares is at $339.8 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares moved upwards by 12.83% to $0.33. BiomX (AMEX:PHGE) stock rose 6.24% to $0.44. The market value of their outstanding shares is at $31.0 million. Virios Therapeutics (NASDAQ:VIRI) stock increased by 6.12% to $0.22. The market value of their outstanding shares is at $6.1 million. Accuray (NASDAQ:ARAY) stock increas
693dINSIDER
SEC Form 3 filed by new insider Pharmacyte Biotech, Inc.
3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
693d13D/G
SEC Form SC 13D filed by MyMD Pharmaceuticals Inc.
SC 13D - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)
700dSEC
MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
702dNEWS
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Rezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago. Mustang Bio (NASDAQ:MBIO) stock increased by 30.64% to $0.41. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 4 days ago. Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 14.77% to $0.87. The company's market cap stands at $31.1 million. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 12.68% to $2.31. The market value of their outstanding shares is at $4.9 million. The company's, Q4 earnings came out 4 days ago. Immunome (NASDAQ:IMNM) shares moved
703dNEWS
PharmaCyte Biotech Makes $7M Investment In MyMD Pharmaceuticals; Investment In Life Sciences Solidifies Previously Announced Strategy To Utilize Significant Cash Position To Create Additional Stockholder Value
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FDA).
703dSEC
MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
703dPR
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD") a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forward in consultation with the U.S. Food and Drug Administration (FD